The Clinical Core seeks to improve the diagnosis and management of individuals with Parkinson disease (PD) through its support of the JHU Udall Center and Clinical Project 3. With this funding period request, the Clinical Core will add biofluid ascertainment (blood, urine, and cerebrospinal fluid (CSF)) to its existing 15-year longitudinal study and brain autopsy program. Through the collection of biofluids from individuals who undergo autopsy the Clinical Core is uniquely situated to allow the Clinical Project to identify PD biomarkers. In addition, to ensure that the Clinical Project has sufficient CSF to complete its aims, the Clinical Core will be responsible for obtaining CSF through collaborations with other cohorts both within and outside JHU. The Clinical Core also seeks to fulfill the mission of the JHU Udall Center through its efforts to educate patients, their families, and health care providers regarding the Center's research activities, PD diagnosis and treatment.

Public Health Relevance

The Clinical Core will be a shared resource of the Parkinson's Disease Research Center and will play a central role in our investigations in the pathogenesis of Parkinson's Disease. The Clinical Core will provide vital support to the Clinical Project 3 through its acquisition of cerebrospinal fluid. It will also support the missions of the other cores and projects through its longitudinal investigation and brain autopsy program as well as education initiatives.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS038377-16
Application #
8882842
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
Project End
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
16
Fiscal Year
2014
Total Cost
$275,400
Indirect Cost
$105,400
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Yun, Seung Pil; Kim, Donghoon; Kim, Sangjune et al. (2018) ?-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol Neurodegener 13:1
Hinkle, Jared T; Perepezko, Kate; Rosenthal, Liana S et al. (2018) Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord 47:50-56
Berger, Nathan A; Besson, Valerie C; Boulares, A Hamid et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192-222
Wu, Xinyan; Zahari, Muhammad Saddiq; Renuse, Santosh et al. (2018) Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clin Proteomics 15:21
Blauwendraat, Cornelis; Pletnikova, Olga; Geiger, Joshua T et al. (2018) Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging :
Heo, Seok; Diering, Graham H; Na, Chan Hyun et al. (2018) Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover. Proc Natl Acad Sci U S A 115:E3827-E3836
Dawson, Ted M; Golde, Todd E; Lagier-Tourenne, Clotilde (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370-1379
Lee, Saebom; Kim, Sangjune; Park, Yong Joo et al. (2018) The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Hum Mol Genet 27:2344-2356
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Yun, Seung Pil; Kam, Tae-In; Panicker, Nikhil et al. (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24:931-938

Showing the most recent 10 out of 250 publications